Ticagrelor as an Alternative for Clopidogrel-Associated Acute Arthritis

Abstract EN

A 65-year-old Caucasian man was hospitalized for a non-ST-elevation myocardial infarction.

On discharge, the patient was started on multiple new medications, including clopidogrel and atorvastatin.

Twenty-six days after discharge, he presented to the Emergency Department (ED) with polyarthralgias.

He was instructed to stop atorvastatin and to follow up with rheumatology and cardiology clinic.

At cardiology clinic follow-up 43 days after ED discharge, clopidogrel was discontinued and patient was switched to ticagrelor.

On follow-up one month later, his symptoms had completely resolved.

During the next 4 months, patient had routine follow-up due to participation in Cardiopulmonary Rehab and he had no cardiac events or recurrence of joint symptoms.

Our patient had no history of arthritis.

Because he initially presented with 2 medication classes associated with arthritis, each was withdrawn separately.

The temporal association of patient’s symptomatic improvement strongly suggests that the arthritis was caused by clopidogrel.

Our patient was able to tolerate ticagrelor with complete resolution of his arthritis and no cardiac events.

Clopidogrel-induced arthritis is a rare adverse drug event.

For patients with a recent drug-eluting stent, alternative antiplatelet therapy with ticagrelor may provide positive cardiac outcomes without similar adverse effects.